The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer [0.03%]
表皮生长因子受体酪氨酸激酶抑制剂和/或化疗作为完全切除的IIIA期非小细胞肺癌术后辅助治疗初探及其五年生存分析研究
Wenyan Ma,Baicheng Zhao,Yukuan Lang et al.
Wenyan Ma et al.
Introduction: Adjuvant chemotherapy or/and adjuvant Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) therapy are commonly used to treat completely resected non-small cell lung cancer (NSCLC) with EGFR...
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study [0.03%]
拉索替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌脑膜转移患者Ⅱ期临床研究：Lazarus研究（KCSG LU 21-01）
Hyun Ae Jung,Tae Min Kim,Hye Ryun Kim et al.
Hyun Ae Jung et al.
Purpose: Lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated high blood-brain barrier (BBB) penetration in preclinical studies. Similarly, pemetrexed has show...
Factors associated with lung cancer-specific mortality in lung cancer screening programs [0.03%]
与肺癌筛查项目中肺癌特异性死亡率相关的因素
Esther Tannoury,Suzanne C Byrne,Mark M Hammer
Esther Tannoury
Objectives: Two major clinical trials have proven lung cancer screening (LCS) to be effective in reducing lung cancer-specific mortality. However, mortality reduction in the trials was only 20%. Our objective is to identi...
The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significance [0.03%]
胸腔SMARCA4基因缺陷型未分化肿瘤免疫荒漠型肿瘤微环境的特征及预后意义
Xiaotao Wang,Wenwen Shi,Yang Xiao et al.
Xiaotao Wang et al.
Introduction: Thoracic SMARCA4-Deficient Undifferentiated Tumors (SMARCA4-UT) are highly aggressive malignancies with poor prognosis. There is currently no standardized treatment strategy. We aimed to investigate the char...
Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancer [0.03%]
血浆蛋白质组分析可识别小细胞肺癌免疫治疗反应的预测生物标志物
Guang-Ling Jie,Jia-Xin Zhong,Jing-Ze Wang et al.
Guang-Ling Jie et al.
Introduction: Immune checkpoint inhibitors have improved clinical outcomes for small-cell lung cancer (SCLC), but patient responses vary widely, and predictive biomarkers remain inadequate. ...
Delivering equitable access to prehabilitation services to optimise outcomes for patients with lung cancer - Best practice recommendations from a UK roundtable event [0.03%]
英国圆桌会议最佳实践建议：向肺癌患者提供公平的康复服务以优化患者预后
William Ricketts,Catherine Sandsund,Zoe Merchant et al.
William Ricketts et al.
Introduction: Prehabilitation in patients with lung cancer has historically been focused on those undergoing surgical resection. However, its benefits could be applicable to those undergoing all forms of treatment both in...
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer [0.03%]
系统评价和网络meta分析：铂类药物难治或耐药的小细胞肺癌的全身治疗评估
Rahul K Desai,Elena J Zhou,Kelvin K W Chan
Rahul K Desai
Background: Platinum-refractory/resistant (r/r) small cell lung cancer (SCLC) is associated with poor prognosis and limited treatment options. While chemotherapy has been the standard, recent randomized controlled trials ...
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO) [0.03%]
意大利放射治疗和临床肿瘤学会(AIRO)关于肺癌间质性肺病患者放射治疗的共识意见
Paolo Borghetti,Rolando D&#x;Angelillo,Giorgio Facheris et al.
Paolo Borghetti et al.
Aim: Interstitial lung diseases (ILD) are a group of disorders affecting the lung parenchyma. ILD patients have a higher risk of lung cancer and worse prognosis, with increased susceptibility to radiotherapy (RT)-related ...
Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy [0.03%]
一项针对肺部癌症筛查计划中临床分期I期肺癌参与者的临床特征和结局的分析：手术与立体定向消融放射治疗的比较——约克郡肺筛查试验报告
Hannah R Bailey,Hui Zhen Tam,Daniel Vulkan et al.
Hannah R Bailey et al.
Background: Lung cancer screening with low-dose computed tomography (LDCT) saves lives by detecting early-stage curable cancer and estimates of overdiagnosis in the previous randomised studies were generally low. Screenin...
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study [0.03%]
体重指数对伴发转移的非小细胞肺癌患者肿瘤治疗电场疗法的影响：来自III期LUNAR研究的事后和模拟分析
Christian Rolfo,David E Gerber,Rupesh Kotecha et al.
Christian Rolfo et al.
Introduction: In the phase III LUNAR study, overall survival (OS) with PD-(L)1 inhibitor or docetaxel was improved by adding Tumor Treating Fields (TTFields) therapy in patients with metastatic non-small cell lung cancer ...